Study of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide

Regulation of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide (Victoza)

The purpose of this study is to determine the effect of exogenous glucagon-like peptide-1 on the immune system i.e on the regulation of immune cells important in diseases such as obesity and diabetes.

The hypotheses are:

• Glucagon-like peptide-1 has an immunological effect observed by studying immune cells in the blood
• Treatment with glucagon-like peptide-1 increases the number of immune cells in the blood
• Treatment with glucagon-like peptide-1 leads to a more anti-inflammatory cytokine profile in the blood

Inclusion Criteria:

• Type 2 diabetes
• BMI > 27 kg/m2
• Planed start of treatment with liraglutide
• Age > 18 years

Exclusion Criteria:

• Infection or active inflammatory disorder
• Immunomodulating treatment (i.e nonsteroidal antiinflammatory drugs, glucocorticoids)
• Smoking
• Alcohol consumption > 14 beverages/week
• Former bariatric surgery